Revelation Biosciences, Inc. is a clinical stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. Revelation was founded in 2020 by industry veterans with a proven track record of successful drug development. Company’s product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD) and its well-established effect on the innate immune system. Revelation has multiple ongoing programs to evaluate Gemini, including GEMINI-SSI as a prevention for post-surgical infection, GEMINI-AKI as a prevention for acute kidney injury, and GEMINI-CKD for the treatment of chronic kidney disease.